Share on StockTwits

Analysts at Piper Jaffray increased their price target on shares of NxStage Medical (NASDAQ:NXTM) from $16.00 to $18.00 in a research report issued to clients and investors on Friday. Piper Jaffray’s price objective would indicate a potential upside of 30.91% from the company’s current price.

Separately, analysts at Canaccord Genuity raised their price target on shares of NxStage Medical from $19.00 to $20.00 in a research note on Friday. They now have a “buy” rating on the stock. One analyst has rated the stock with a sell rating and one has issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $18.25.

Shares of NxStage Medical (NASDAQ:NXTM) traded down 1.64% during mid-day trading on Friday, hitting $13.76. The stock had a trading volume of 374,718 shares. NxStage Medical has a 52 week low of $8.77 and a 52 week high of $15.65. The stock has a 50-day moving average of $13.7 and a 200-day moving average of $13.28. The company’s market cap is $845.1 million.

NxStage Medical (NASDAQ:NXTM) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.12) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.11) by $0.01. The company had revenue of $74.10 million for the quarter, compared to the consensus estimate of $70.52 million. During the same quarter last year, the company posted ($0.06) earnings per share. NxStage Medical’s revenue was up 13.3% compared to the same quarter last year. On average, analysts predict that NxStage Medical will post $-0.42 earnings per share for the current fiscal year.

In other NxStage Medical news, CEO Jeffrey H. Burbank sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $14.00, for a total value of $70,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

NxStage Medical, Inc (NASDAQ:NXTM) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures.

Receive News & Ratings for NxStage Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.